FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immune Disease topics
Immune Disease
Autoimmune
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Transplant
Autoimmune Disorders
Type 1 Diabetes
Autoimmune Disorder
Proliferative Disorder
Signs And Symptoms
Proliferative
Antagonist
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Disease patents



      
           
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS RSS


Date/App# patent app List of recent Immune Disease-related patents
01/22/15
20150024459
 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors patent thumbnailnew patent Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.
01/22/15
20150024391
 Compositions and methods for detecting allogeneic matter in a subject patent thumbnailnew patent Compositions and methods for detecting allogeneic matter in a subject
The present disclosure provides a panel of nucleic acid molecule primers specific for hla-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.. .
Fred Hutchinson Cancer Research Center
01/22/15
20150023976
 Antibody polypeptides that antagonize cd40l patent thumbnailnew patent Antibody polypeptides that antagonize cd40l
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited
01/22/15
20150023870
 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases patent thumbnailnew patent Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
Disclosed herein are compositions and methods of use comprising hexavalent dnl complexes. Preferably, the complexes comprise anti-cd20 and/or anti-cd22 antibodies or fragments thereof.
Ibc Pharmaceuticals, Inc.
01/15/15
20150018516
 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer patent thumbnailPro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc.
01/15/15
20150018401
 Novel ep4 agonist patent thumbnailNovel ep4 agonist
Wherein r1 and r2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, r3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known pgi2 analogs, a selective ep4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.. .
01/15/15
20150018336
 Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors patent thumbnailPyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
01/15/15
20150018329
 Pharmaceutically active pyrazolo-triazine derivatives patent thumbnailPharmaceutically active pyrazolo-triazine derivatives
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase..
Lead Discovery Center Gmbh
01/15/15
20150018251
 Protein chips, preparation and use thereof patent thumbnailProtein chips, preparation and use thereof
The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal.
Universite Claude Bernard Lyon 1
01/15/15
20150017164
 Combination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease patent thumbnailCombination of blys and/or april inhibition and immunosuppressants for treatment of autoimmune disease
The invention relates to novel combination therapies involving blys or blys/april inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the blys and/or april antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Ares Trading S.a.
01/15/15
20150017132

Mesenchymal stem cells and uses therefor


Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
Mesoblast International Sárl
01/08/15
20150011767

Use of koumine and its homologues in preparation of medicament for treatment of autoimmune diseases of involved bones and joints


The present invention discloses an application of koumine and homologue thereof in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like, in particular an application of gelsemium alkaloid monomer koumine and homologue thereof or pharmaceutically acceptable salt thereof as active ingredient in preparation of drugs for treating autoimmune diseases involving bones and joints including rheumatoid arthritis, spondylitis ankylopoietica or the like. The result of pharmacology experiment shows that koumine can decrease the generation of organism antibody against autoimmune diseases involving bones and joints in a dose dependent manner, improve symptoms of swelling and hyperalgesia, reduce arthritis index, reverse joint pathological changes, and has no serious shortage of commonly used clinical drugs; thus koumine has an effect against autoimmune diseases involving bones and joints including rheumatoid arthritis, ankylosing spondylitis etc.
Fujian Medical University
01/08/15
20150010588

Aromatic-cationic peptides and uses of same


The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport, inhibition of cardiolipin peroxidation, and inhibition of apoptosis and necrosis to treat, prevent or ameliorate the symptoms of autoimmune diseases or condition..
Cornell University
01/01/15
20150005230

Cyclodextrin-based polymers for therapeutic delivery


Provided are methods relating to the use of cdp-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are cdp-therapeutic agent conjugates, particles comprising cdp-therapeutic agent conjugates, and compositions comprising cdp-therapeutic agent conjugates..
Cerulean Pharma Inc.
01/01/15
20150004182

Population of immunoregulatory t cells specific for an irrelevant antigen and uses thereof for preventing or treating immune diseases


The present invention relates to methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (gvhd) using populations or compositions of immunoregulatory t cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.. .
Universite Paris Est Creteil Val De Marne
01/01/15
20150004178

Anti-human sema4a antibodies useful to treat disease


Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
12/25/14
20140378475

Substituted tetrahydrocarbazole and carbazole carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is cl or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140378446

Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.
12/25/14
20140378371

Cytokine receptor peptides, compositions thereof and methods thereof


The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.
12/25/14
20140377291

Glycosphingolipids for use in modulating immune responses


Provided herein are sphingolipid compounds that are useful for activating natural killer t cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer t cells.
President And Fellows Of Harvard College
12/18/14
20140371445

Quinic acid derivative, process for preparation and uses thereof


The present invention relates to a quinic acid derivative, preparation process of the same and pharmaceutical uses thereof. The quinic acid derivative has a quinic acid-like structure which binds to cd28, blocks t-cell signal 2 pathway via cd28, and suppresses t-cell activation.
National Applied Research Laboratories
12/18/14
20140371307

Sirt 1 activator including syringaresinol


The present invention relates to a compound of formula 1, and an sirt 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the sirt 1 activator for detoxification, for the improvement of metabolic disorders, for the prevention or improvement of eye diseases, or the prevention or improvement of immune diseases..
Amorepacific Corporation
12/18/14
20140371292

Method for the controlled intracellular delivery of nucleic acids


The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier molecules, wherein at least a part of the one or more carrier molecules in the polymeric complex are covalently attached to hydroxyalkyl starch, and wherein the hydroxyalkyl starch is shielding the polymeric complex; allowing the shielded polymeric complex to get into contact with the one or more target cells; deshielding the polymeric complex by removing the hydroxyalkyl starch; and allowing the deshielded polymeric complex to internalize into the one or more target cells. Removal of the hydroxyalkyl starch can be accomplished enzymatically by exposing the polymeric complex to amylase.
Ludwig-maximilians-universitat Munchen
12/18/14
20140371272

Therapeutic compounds


The invention provides compounds of formula (i) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (i), processes for preparing compounds of formula (i), intermediates useful for preparing compounds of formula (i) and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula (i)..
Regents Of The University Of Minnesota
12/18/14
20140371242

Azathioprine oral suspensions and methods of use


Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms.
Professional Compounding Centers Of America
12/18/14
20140371198

Novel compounds useful for the treatment of metabolic and inflammatory diseases


These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.. .
12/18/14
20140371177

Treatment of cancer, inflammatory disease, and autoimmune disease


A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate..
Androscience Corporation
12/18/14
20140371132

Codon signature for neuromyelitis optica


The present invention provides for the diagnosis and prediction of neuromyelitis optica (nmo) in subject utilizing a unique a codon signature in b cells that has now been associated with nmo and not with any other autoimmune disease. More particularly, the method may comprise the steps of (a) providing a 10 b-cell containing sample from a subject, or dna or rna isolated therefrom; (b) determining the vh1 and/or vh4 structure of vh1nh4-expressing b-cells from said subject, (c) determining the mutational frequency vh1 and/or vh4 genes; (d) identifying the presence or absence of a codon signature associated with nmo or risk of nmo; and (e) selecting patients exhibiting said codon signature..
The Board Of Regents Of The University Of Texas System
12/18/14
20140371103

Methods and reagents for evaluating autoimmune disease and determining antibody repertoire


The invention provides methods and kits for determining an antibody or t-cell receptor repertoire in a sample containing b-cells and/or t-cells, and provides a method for evaluating a patient for the presence of an autoimmune disorder.. .
Diogenix, Inc.


Popular terms: [SEARCH]

Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.5662

4695

1 - 1 - 90